Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer

BackgroundStudies have demonstrated lower rates of breast cancer survival for Black versus White women. Factors implicated include later stages at diagnosis, differences in tumor biology, and lower compliance rates to adjuvant hormone therapy (AHT) among Black women with hormone sensitive breast cancer. We examined factors associated with compliance to AHT among Black and White women with invasive breast cancer.MethodsWomen with estrogen receptor positive (ER+), non-metastatic breast cancer were identified by the cancer registry at the University of Chicago Hospital and asked to complete a mail-in survey. Compliance was defined by self-reported adherence to AHT ≥80% at the time of the survey plus medical record verification of persistence (completion of 5 years of AHT). Logistic regression was used to determine factors associated with compliance to AHT.Results197 (135 White and 62 Black) women were included in the analysis. 97.4% of patients reported adherence to therapy. 87.4% were found to be persistent to therapy. Overall compliance was 87.7% with no statistically significant racial difference seen (87.9% in White and 87.0% in Black, P = 0.87). For both Black and White women, compliance was strongly associated with both perceived importance of AHT (OR =2.1, 95% CI:1.21-3.68, P = 0.009) and the value placed on their doctor’s opinion about the importance of AHT (OR = 4.80, 95% CI: 2.03-11.4, P < 0.001).ConclusionsIn our cohort of Black and White women, perceived importance of AHT and the degree to which they valued their doctor’s opinion correlated with overall compliance. This suggests that Black and White women consider similar factors in their decision to take AHT.

[1]  C. Stavropoulou.  Non-adherence to medication and doctor-patient relationship: Evidence from a European survey. , 2011, Patient education and counseling.

[2]  Matthew P Goetz,et al.  Early discontinuation of tamoxifen , 2007, Cancer.

[3]  H. Earl,et al.  aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Tarpin,et al.  Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view , 2010, Psycho-oncology.

[5]  M. Hameed,et al.  Barriers to adequate follow-up during adjuvant therapy may be important factors in the worse outcome for Black women after breast cancer treatment , 2008, World journal of surgical oncology.

[6]  A. Neugut,et al.  Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study , 2013, Breast Cancer Research and Treatment.

[7]  A. Neugut,et al.  The Breast Cancer Quality of Care Study (BQUAL): A Multi‐Center Study to Determine Causes for Noncompliance with Breast Cancer Adjuvant Therapy , 2012, The breast journal.

[8]  Timothy L. Lash,et al.  Adherence to tamoxifen over the five-year course , 2006, Breast Cancer Research and Treatment.

[9]  Dawn L. Hershman,et al.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.

[10]  Hong-wei Zhang,et al.  A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer , 2012, Breast Cancer Research and Treatment.

[11]  Eric C. Schneider,et al.  Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use , 2007, Medical care.

[12]  Jerry Avorn,et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Camacho,et al.  Adjuvant hormonal therapy use among insured, low-income women with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Martino,et al.  Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Grunfeld,et al.  Adherence beliefs among breast cancer patients taking tamoxifen. , 2005, Patient education and counseling.

[16]  Sally W. Vernon,et al.  Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review , 2012, Breast Cancer Research and Treatment.

[17]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[18]  J. Espinàs,et al.  Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain , 2012, British Journal of Cancer.

[19]  B. Svarstad,et al.  Effects of physician communication style on client medication beliefs and adherence with antidepressant treatment. , 2000, Patient education and counseling.

[20]  M. Stockler,et al.  What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? , 2005, The Lancet. Oncology.

[21]  S. Kaplan,et al.  Assessing the Effects of Physician-Patient Interactions on the Outcomes of Chronic Disease , 1989, Medical care.

[22]  Aliza K Fink,et al.  Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Gustafson,et al.  The roles of past behavior and health beliefs in predicting medication adherence to a statin regimen , 2012, Patient preference and adherence.

[24]  J. Weinman,et al.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. , 1999, Journal of psychosomatic research.

[25]  T. Lash,et al.  Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[27]  S. Kucukarslan.  A review of published studies of patients' illness perceptions and medication adherence: lessons learned and future directions. , 2012, Research in social & administrative pharmacy : RSAP.

[28]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[29]  J. Steiner,et al.  Dyslipidemia: Factors Related to Adherence to Statin Therapy , 2007, The Annals of pharmacotherapy.

[30]  L. Huiart,et al.  Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  C. Hudis,et al.  Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. , 2008, Clinical breast cancer.